Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Equifax heads into its October 20 results with short sellers in full retreat and options traders pivoting away from the defensive crouch they held for most of the quarter.
The most striking signal is how fast the bearish positioning has unwound. Short interest fell 31% over the past week to 4.1% of the free float, dropping from roughly 7.4 million shares in early October to just over 5 million. Borrow is cheap at 0.35% and availability is exceptionally loose, more than 57 shares available for every one already borrowed, so there is no mechanical pressure forcing covers. Shorts are leaving because they want to, not because the lending market is closing on them. Options tell the same story from a different angle: the put/call ratio dropped sharply to 1.45 on Thursday, more than two standard deviations below its 20-day average of 1.93, near the lowest reading of the past year. After weeks of elevated put demand, traders shifted toward calls heading into the release, a clear pivot in sentiment.
The analyst community is less certain. Every major revision in the past two weeks has been a target cut: Morgan Stanley trimmed to $205 from $225 on October 13, keeping an Overweight; Needham cut to $190 from $245 on the same day; and Oppenheimer went further, downgrading outright to Perform on October 16. RBC Capital also reduced its target to $177 from $194 while holding Outperform. The stock trades at $161.25, well below the consensus mean target of $196, and the consensus remains Buy with 12 buy ratings against 6 holds. Bulls focus on mid-single-digit USIS revenue growth, expected EBITDA margin expansion of around 100 basis points year-over-year, and the company's pricing power in FICO scores. Bears cite mortgage origination headwinds, the risk of a 10% earnings decline if volumes disappoint, and slower international revenue growth in markets like Canada and the UK.
The peer group adds texture to the week's move. TransUnion, the closest comparable with an 87% correlation, surged 10.7% on Thursday and 14.8% over the week, a rally that likely pulled EFX along with it. Equifax's own 10.6% weekly gain came after a month down 3.5%, suggesting the bounce reflects sector rotation and short covering rather than a fundamental re-rating. The ORTEX short score has dropped sharply, from around 44 to 37.6 since October 8, confirming the shift in positioning. The ORTEX index rebalance model puts a 70% probability on EFX joining the CRSP US Small cap index at the December quarterly review, which would require the stock to close above $179.60 to qualify. That is 11% above Thursday's close. The potential buying flow of $302 million, or roughly 1.1 days of normal volume, is a mechanical fact hanging over the December timeframe, independent of Monday's earnings.
The print will test whether the sharp short cover and call-side options shift were prescient or premature, specifically whether Equifax's mortgage-exposed revenue mix can demonstrate enough recovery to validate a stock that still sits 3.5% below where it was a month ago.
See the live data behind this article on ORTEX.
Open EFX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
